https://www.pharmaradar360.com/article/13db037a7d2b68dbPharmaRadar360en2026-05-05T11:00:00.000ZRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026https://www.pharmaradar360.com/article/e0253f11bcfbc844PharmaRadar360en2026-05-05T10:45:00.000ZLilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four yearshttps://www.pharmaradar360.com/article/1eb1ba15260a2dddPharmaRadar360en2026-05-05T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/8c34f94ae28ba0e5PharmaRadar360en2026-05-05T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/ebed76581ab90727PharmaRadar360en2026-05-05T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/7ac30b21a08fc53fPharmaRadar360en2026-05-05T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/28c2356a919be57aPharmaRadar360en2026-05-05T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/cbe648c93019578ePharmaRadar360en2026-05-05T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/58fc7435d3ac444aPharmaRadar360en2026-05-05T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/944734f24c93ee5dPharmaRadar360en2026-05-05T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/ee5728be6285cfecPharmaRadar360en2026-05-05T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/fadfdb20390338aePharmaRadar360en2026-05-05T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/c89dde426141cda9PharmaRadar360en2026-05-05T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/7c23cafe02234f47PharmaRadar360en2026-05-05T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/4877c45776b67816PharmaRadar360en2026-05-05T00:00:00.000Z6203https://www.pharmaradar360.com/article/480b7aa70c073bd1PharmaRadar360en2026-05-05T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/30c7aa16955a60a9PharmaRadar360en2026-05-04T16:00:00.000ZBio Korea 2026: US policy risks shift to execution frameworkhttps://www.pharmaradar360.com/article/ce558c2c6fc30eafPharmaRadar360en2026-05-04T15:21:38.000ZLa AEMPS actualiza la información sobre el sistema de vigilancia de productos sanitarios y las funciones del responsable de vigilancia de los centros sanitarioshttps://www.pharmaradar360.com/article/964435f66836529ePharmaRadar360en2026-05-04T15:11:00.000ZLilly declares second-quarter 2026 dividendhttps://www.pharmaradar360.com/article/5d58c5d11e0383b8PharmaRadar360en2026-05-04T14:41:36.000ZRaport: Przyspieszenie badań klinicznych to 257 mln zł dla gospodarki i nowoczesne leczenie dla Polakówhttps://www.pharmaradar360.com/article/f171945efe26209ePharmaRadar360en2026-05-04T13:03:52.000ZApós 30 anos, a Lei de Propriedade Industrial precisa evoluir, afirma presidente da Interfarmahttps://www.pharmaradar360.com/article/7877aadba697fa58PharmaRadar360en2026-05-04T12:30:52.000ZAcompanhe o Summit Propriedade Intelectual na Agenda Públicahttps://www.pharmaradar360.com/article/8810a9c11582abccPharmaRadar360en2026-05-04T12:25:44.000ZEU Innovation Network (EU IN)https://www.pharmaradar360.com/article/128b0ca31a9ae746PharmaRadar360en2026-05-04T10:59:00.000ZBristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™https://www.pharmaradar360.com/article/1fe4bc9f7ed46c64PharmaRadar360en2026-05-04T10:55:23.000ZANMAT y el Ministerio de Salud de la Nación acuerdan un nuevo marco para los productos de tabaco y nicotina